<DOC>
	<DOCNO>NCT00376064</DOCNO>
	<brief_summary>This study investigate efficacy combination treatment octreotide acetate cabergoline acromegalic patient partially responsive somatostatin analog monotherapy</brief_summary>
	<brief_title>Efficacy Octreotide Acetate Cabergoline Patients With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>Inclusion criterion : Male female patient ( &gt; 18 year ) prior surgery micro macroadenoma pituitary . At least 6 month chronic treatment 30mg octreotide ( long act release ) . Partial responsiveness , define follow : one point within 6 month monotherapy 30mg/month octreotide ( long act release ) patient must experience decrease GH IGF1 least 25 % compare premonotherapy value ( = baseline ) . Note : For efficacy analysis GH IGF1values measure central laboratory visit 1 ( =study baseline ) use . Lack suppression GH nadir &lt; 1.0 µg/L , oral administration 75 g glucose ( OGTT ) IGFI level least 10 % normal value ± 2 SD ( adjust age gender ; Brabant 2003 ) must prove within 4 week prior visit 1 . However , acromegaly symptom inadequately control defined acromegaly comorbidities symptom evaluation ( judged investigator ) , abnormal GH IGF1value define sufficient . Patient 's write informed consent . Exclusion criterion : Requires surgery recent significant deterioration visual field neurological sign , relate pituitary tumor mass . Radiotherapy plan radiotherapy acromegaly within last 2 year . Symptomatic cholelithiasis clinically relevant . Receiving treatment dopamine agonist within last 6 month prior treatment GHreceptorantagonists . Patients renal insufficiency , RaynaudSyndrome gastrointestinal ulcer/ bleeding include study psychose anamnesis . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Growth hormone ( GH )</keyword>
	<keyword>IGF-1</keyword>
	<keyword>Acromegaly</keyword>
	<keyword>Pituitary adenoma</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Brain cancer</keyword>
	<keyword>Octreotide acetate</keyword>
</DOC>